|
1
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2012. CA Cancer J Clin. 62:10–29. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
O'Neill VJ and Twelves CJ: Oral cancer
treatment: Developments in chemotherapy and beyond. Br J Cancer.
87:933–937. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Gibson MK and Forastiere AA: Reassessment
of the role of induction chemotherapy for head and neck cancer.
Lancet Oncol. 7:565–574. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Tsukada H, Yokoyama A, Goto K, Shinkai T,
Harada M, Ando M, Shibata T, Ohe Y, Tamura T and Saijo N: Lung
Cancer Study Group of the Japan Clinical Oncology Group (JCOG):
Randomized controlled trial comparing docetaxel-cisplatin
combination with weekly docetaxel alone in elderly patients with
advanced non-small-cell lung cancer: Japan Clinical Oncology Group
(JCOG) 0207. Jpn J Clin Oncol. 45:88–95. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Li W, Wan L, Zhai LY and Wang J: Effects
of SC-560 in combination with cisplatin or taxol on angiogenesis in
human ovarian cancer xenografts. Int J Mol Sci. 15:19265–19280.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Hu MH, Wang LW, Lu HJ, Chu PY, Tai SK, Lee
TL, Chen MH, Yang MH and Chang PM: Cisplatin-based chemotherapy
versus cetuximab in concurrent chemoradiotherapy for locally
advanced head and neck cancer treatment. BioMed Res Int.
2014:9043412014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wang L, Zhang Y, Zhao J, Xiao E, Lu J, Fu
S and Wang Z: Combination of bladder cancer-specific oncolytic
adenovirus gene therapy with cisplatin on bladder cancer in vitro.
Tumour Biol. 35:10879–10890. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wang B, Zhang S, Yue K and Wang XD: The
recurrence and survival of oral squamous cell carcinoma: A report
of 275 cases. Chin J Cancer. 32:614–618. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Galluzzi L, Senovilla L, Vitale I, Michels
J, Martins I, Kepp O, Castedo M and Kroemer G: Molecular mechanisms
of cisplatin resistance. Oncogene. 31:1869–1883. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wang X, Martindale JL and Holbrook NJ:
Requirement for ERK activation in cisplatin-induced apoptosis. J
Biol Chem. 275:39435–39443. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Mandic A, Hansson J, Linder S and Shoshan
MC: Cisplatin induces endoplasmic reticulum stress and
nucleus-independent apoptotic signaling. J Biol Chem.
278:9100–9106. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhou XJ, Chen WT, Li Q and He RG:
Establishment and biological characteristics of cisplatin resistant
cell line from human tongue squamous cell carcinoma Tca8113.
Shanghai Kou Qiang Yi Xue. 10:31–34. 2001.(In Chinese). PubMed/NCBI
|
|
14
|
Lu SC: Glutathione synthesis. Biochim
Biophys Acta. 1830:3143–3153. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Okuno S, Sato H, Kuriyama-Matsumura K,
Tamba M, Wang H, Sohda S, Hamada H, Yoshikawa H, Kondo T and Bannai
S: Role of cystine transport in intracellular glutathione level and
cisplatin resistance in human ovarian cancer cell lines. Br J
Cancer. 88:951–956. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wangpaichitr M, Sullivan EJ,
Theodoropoulos G, Wu C, You M, Feun LG, Lampidis TJ, Kuo MT and
Savaraj N: The relationship of thioredoxin-1 and cisplatin
resistance: Its impact on ROS and oxidative metabolism in lung
cancer cells. Mol Cancer Ther. 11:604–615. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wangpaichitr M, Wu C, You M, Maher JC,
Dinh V, Feun LG and Savaraj N:
N',N'-Dimethyl-N',N'-bis(phenylcarbonothioyl) propanedihydrazide
(elesclomol) selectively kills cisplatin resistant lung cancer
cells through reactive oxygen species (ROS). Cancers (Basel).
1:23–38. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Sato H, Tamba M, Ishii T and Bannai S:
Cloning and expression of a plasma membrane cystine/glutamate
exchange transporter composed of two distinct proteins. J Biol
Chem. 274:11455–11458. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ye P, Mimura J, Okada T, Sato H, Liu T,
Maruyama A, Ohyama C and Itoh K: Nrf2- and ATF4-dependent
upregulation of xCT modulates the sensitivity of T24 bladder
carcinoma cells to proteasome inhibition. Mol Cell Biol.
34:3421–3434. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wada T, Ishimoto T, Seishima R,
Tsuchihashi K, Yoshikawa M, Oshima H, Oshima M, Masuko T, Wright
NA, Furuhashi S, et al: Functional role of CD44v-xCT system in the
development of spasmolytic polypeptide-expressing metaplasia.
Cancer Sci. 104:1323–1329. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Takeuchi S, Wada K, Toyooka T, Shinomiya
N, Shimazaki H, Nakanishi K, Nagatani K, Otani N, Osada H, Uozumi
Y, et al: Increased xCT expression correlates with tumor invasion
and outcome in patients with glioblastomas. Neurosurgery. 72:33–41.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Huang Y, Dai Z, Barbacioru C and Sadée W:
Cystine-glutamate transporter SLC7A11 in cancer chemosensitivity
and chemoresistance. Cancer Res. 65:7446–7454. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Savaskan NE, Heckel A, Hahnen E, Engelhorn
T, Doerfler A, Ganslandt O, Nimsky C, Buchfelder M and Eyüpoglu IY:
Small interfering RNA-mediated xCT silencing in gliomas inhibits
neurodegeneration and alleviates brain edema. Nat Med. 14:629–632.
2008. View
Article : Google Scholar : PubMed/NCBI
|
|
24
|
Toyoda M, Kaira K, Ohshima Y, Ishioka NS,
Shino M, Sakakura K, Takayasu Y, Takahashi K, Tominaga H, Oriuchi
N, et al: Prognostic significance of amino-acid transporter
expression (LAT1, ASCT2, and xCT) in surgically resected tongue
cancer. Br J Cancer. 110:2506–2513. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
El-Sawalhi MM and Ahmed LA: Exploring the
protective role of apocynin, a specific NADPH oxidase inhibitor, in
cisplatin-induced cardiotoxicity in rats. Chem Biol Interact.
207:58–66. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Tanabe M, Izumi H, Ise T, Higuchi S,
Yamori T, Yasumoto K and Kohno K: Activating transcription factor 4
increases the cisplatin resistance of human cancer cell lines.
Cancer Res. 63:8592–8595. 2003.PubMed/NCBI
|
|
27
|
Lo M, Wang YZ and Gout PW: The
xc− cystine/glutamate antiporter: A potential target for
therapy of cancer and other diseases. J Cell Physiol. 215:593–602.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Guo W, Zhao Y, Zhang Z, Tan N, Zhao F, Ge
C, Liang L, Jia D, Chen T, Yao M, et al: Disruption of xCT inhibits
cell growth via the ROS/autophagy pathway in hepatocellular
carcinoma. Cancer Lett. 312:55–61. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Huang Z, Guo KJ, Guo RX and He SG: Effects
of 5-fluouracil combined with sulfasalazine on human pancreatic
carcinoma cell line BxPC-3 proliferation and apoptosis in vitro.
Hepatobiliary Pancreat Dis Int. 6:312–320. 2007.PubMed/NCBI
|
|
30
|
Lay JD, Hong CC, Huang JS, Yang YY, Pao
CY, Liu CH, Lai YP, Lai GM, Cheng AL, Su IJ and Chuang SE:
Sulfasalazine suppresses drug resistance and invasiveness of lung
adenocarcinoma cells expressing AXL. Cancer Res. 67:3878–3887.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Awasthi S, Sharma R, Singhal SS, Herzog
NK, Chaubey M and Awasthi YC: Modulation of cisplatin cytotoxicity
by sulphasalazine. Br J Cancer. 70:190–194. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Newton GL, Dorian R and Fahey RC: Analysis
of biological thiols: Derivatization with monobromobimane and
separation by reverse-phase high-performance liquid chromatography.
Anal Biochem. 114:383–387. 1981. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Ishimoto T, Nagano O, Yae T, Tamada M,
Motohara T, Oshima H, Oshima M, Ikeda T, Asaba R, Yagi H, et al:
CD44 variant regulates redox status in cancer cells by stabilizing
the xCT subunit of system xc(−) and thereby promotes
tumor growth. Cancer Cell. 19:387–400. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Ren W, Wang X, Gao L, Li S, Yan X, Zhang
J, Huang C, Zhang Y and Zhi K: MiR-21 modulates chemosensitivity of
tongue squamous cell carcinoma cells to cisplatin by targeting
PDCD4. Mol Cell Biochem. 390:253–262. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Qin J, Luo M, Qian H and Chen W:
Upregulated miR-182 increases drug resistance in cisplatin-treated
HCC cell by regulating TP53INP1. Gene. 538:342–347. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Zhang N, Dai L, Qi Y, Di W and Xia P:
Combination of FTY720 with cisplatin exhibits antagonistic effects
in ovarian cancer cells: Role of autophagy. Int J Oncol.
42:2053–2059. 2013.PubMed/NCBI
|
|
37
|
Li Y, Li X, Wong YS, Chen T, Zhang H, Liu
C and Zheng W: The reversal of cisplatin-induced nephrotoxicity by
selenium nanoparticles functionalized with 11-mercapto-1-undecanol
by inhibition of ROS-mediated apoptosis. Biomaterials.
32:9068–9076. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Barros MP, Marin DP, Bolin AP, de Cássia
Santos Macedo R, Campoio TR, Fineto C Jr, Guerra BA, Polotow TG,
Vardaris C, Mattei R and Otton R: Combined astaxanthin and fish oil
supplementation improves glutathione-based redox balance in rat
plasma and neutrophils. Chem Biol Interact. 197:58–67. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Gout PW, Buckley AR, Simms CR and
Bruchovsky N: Sulfasalazine, a potent suppressor of lymphoma growth
by inhibition of the x(c)− cystine transporter: A new
action for an old drug. Leukemia. 15:1633–1640. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
You BR and Park WH: Arsenic trioxide
induces human pulmonary fibroblast cell death via increasing ROS
levels and GSH depletion. Oncol Rep. 28:749–757. 2012.PubMed/NCBI
|
|
41
|
Park WH and Kim SH: MG132, a proteasome
inhibitor, induces human pulmonary fibroblast cell death via
increasing ROS levels and GSH depletion. Oncol Rep. 27:1284–1291.
2012.PubMed/NCBI
|
|
42
|
You BR and Park WH: Suberoyl bishydroxamic
acid-induced apoptosis in HeLa cells via ROS-independent,
GSH-dependent manner. Mol Biol Rep. 40:3807–3816. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Torre C, Wang SJ, Xia W and Bourguignon
LY: Reduction of hyaluronan-CD44-mediated growth, migration, and
cisplatin resistance in head and neck cancer due to inhibition of
Rho kinase and PI-3 kinase signaling. Arch Otolaryngol Head Neck
Surg. 136:493–501. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Cao J, Dai DL, Yao L, Yu HH, Ning B, Zhang
Q, Chen J, Cheng WH, Shen W and Yang ZX: Saturated fatty acid
induction of endoplasmic reticulum stress and apoptosis in human
liver cells via the PERK/ATF4/CHOP signaling pathway. Mol Cell
Biochem. 364:115–129. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Zinszner H, Kuroda M, Wang X, Batchvarova
N, Lightfoot RT, Remotti H, Stevens JL and Ron D: CHOP is
implicated in programmed cell death in response to impaired
function of the endoplasmic reticulum. Genes Dev. 12:982–995. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Oyadomari S and Mori M: Roles of
CHOP/GADD153 in endoplasmic reticulum stress. Cell Death Differ.
11:381–389. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Horndasch M, Lienkamp S, Springer E,
Schmitt A, Pavenstädt H, Walz G and Gloy J: The C/EBP homologous
protein CHOP (GADD153) is an inhibitor of Wnt/TCF signals.
Oncogene. 25:3397–3407. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Tetsu O and McCormick F: Beta-catenin
regulates expression of cyclin D1 in colon carcinoma cells. Nature.
398:422–426. 1999. View
Article : Google Scholar : PubMed/NCBI
|
|
49
|
Zhang X, Gaspard JP and Chung DC:
Regulation of vascular endothelial growth factor by the Wnt and
K-ras pathways in colonic neoplasia. Cancer Res. 61:6050–6054.
2001.PubMed/NCBI
|
|
50
|
Fujita M, Furukawa Y, Tsunoda T, Tanaka T,
Ogawa M and Nakamura Y: Up-regulation of the ectodermal-neural
cortex 1 (ENC1) gene, a downstream target of the
beta-catenin/T-cell factor complex, in colorectal carcinomas.
Cancer Res. 61:7722–7726. 2001.PubMed/NCBI
|
|
51
|
Bao LJ, Jaramillo MC, Zhang ZB, Zheng YX,
Yao M, Zhang DD and Yi XF: Nrf2 induces cisplatin resistance
through activation of autophagy in ovarian carcinoma. Int J Clin
Exp Pathol. 7:1502–1513. 2014.PubMed/NCBI
|
|
52
|
Hayden A, Douglas J, Sommerlad M, Andrews
L, Gould K, Hussain S, Thomas GJ, Packham G and Crabb SJ: The Nrf2
transcription factor contributes to resistance to cisplatin in
bladder cancer. Urol Oncol. 32:806–814. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Li M, Jin J, Li J, Guan CW, Wang WW, Qiu
YW and Huang ZY: Schisandrin B protects against nephrotoxicity
induced by cisplatin in HK-2 cells via Nrf2-ARE activation. Yao Xue
Xue Bao. 47:1434–1439. 2012.(In Chinese). PubMed/NCBI
|
|
54
|
Sahin K, Tuzcu M, Gencoglu H, Dogukan A,
Timurkan M, Sahin N, Aslan A and Kucuk O:
Epigallocatechin-3-gallate activates Nrf2/HO-1 signaling pathway in
cisplatin-induced nephrotoxicity in rats. Life Sci. 87:240–245.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Aleksunes LM, Goedken MJ, Rockwell CE,
Thomale J, Manautou JE and Klaassen CD: Transcriptional regulation
of renal cytoprotective genes by Nrf2 and its potential use as a
therapeutic target to mitigate cisplatin-induced nephrotoxicity. J
Pharmacol Exp Ther. 335:2–12. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Luke DR, Vadiei K and Lopez-Berestein G:
Role of vascular congestion in cisplatin-induced acute renal
failure in the rat. Nephrol Dial Transplant. 7:1–7. 1992.PubMed/NCBI
|
